114 related articles for article (PubMed ID: 29088977)
1. Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.
Awada G; de Azambuja E; Awada A
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1205-1215. PubMed ID: 29088977
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
Xie W; Zheng F; Song X; Zhong B; Yan L
Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibitors and beta blockers in chronic congestive cardiac failure: therapeutic basis.
Manoria PC; Manoria P
J Indian Med Assoc; 2003 May; 101(5):311-2, 315. PubMed ID: 14575221
[TBL] [Abstract][Full Text] [Related]
5. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.
Raimondi S; Botteri E; Munzone E; Cipolla C; Rotmensz N; DeCensi A; Gandini S
Int J Cancer; 2016 Jul; 139(1):212-9. PubMed ID: 26916107
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials.
Yang Y; Wang R; Li MX; Xing Y; Li WG
Int J Cardiol; 2016 Sep; 219():350-7. PubMed ID: 27352206
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic therapies across the continuum of left ventricular dysfunction.
Abraham WT; Greenberg BH; Yancy CW
Am J Cardiol; 2008 Sep; 102(5A):21G-28G. PubMed ID: 18722188
[TBL] [Abstract][Full Text] [Related]
8. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
[TBL] [Abstract][Full Text] [Related]
9. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
[TBL] [Abstract][Full Text] [Related]
10. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
12. [Cardioprotective treatment during adjuvant cancer therapy].
Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
[TBL] [Abstract][Full Text] [Related]
13. Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
Sarocchi M; Arboscello E; Ghigliotti G; Murialdo R; Bighin C; Gualandi F; Sicbaldi V; Balbi M; Brunelli C; Spallarossa P
Chemotherapy; 2018; 63(6):315-320. PubMed ID: 30840967
[TBL] [Abstract][Full Text] [Related]
14. Prevention of heart failure.
Cohn JN
Cardiology; 1999; 92 Suppl 1():22-5; discussion 26-8. PubMed ID: 10652968
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial.
Heck SL; Gulati G; Ree AH; Schulz-Menger J; Gravdehaug B; Røsjø H; Steine K; Bratland A; Hoffmann P; Geisler J; Omland T
Cardiology; 2012; 123(4):240-7. PubMed ID: 23207160
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.
Düngen HD; Kober L; Nodari S; Schou M; Otto C; Becka M; Kanefendt F; Winkelmann BR; Gislason G; Richard F; Nielsen OW; Gheorghiade M; Senni M
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):942-951. PubMed ID: 30452784
[TBL] [Abstract][Full Text] [Related]
17. Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management.
Rudo TJ; Kowey PR
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I58-63. PubMed ID: 16450814
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
19. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389
[TBL] [Abstract][Full Text] [Related]
20. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial.
Bosch X; Esteve J; Sitges M; de Caralt TM; Domènech A; Ortiz JT; Monzó M; Morales-Ruiz M; Perea RJ; Rovira M
J Card Fail; 2011 Aug; 17(8):643-8. PubMed ID: 21807325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
